| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB400-105SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-89474SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-80652-0.1mg | |||
| BSA Free | NB100-77417SS | |||
| Azide and BSA Free | NBP2-80652 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-40766SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2379SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP1-28667SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1327SS | |||
| Azide and BSA Free | NBP2-80626 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-64895SS | |||
| Azide and BSA Free | NBP2-80651 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2068SS | |||
| Azide and BSA Free | NBP2-80554 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB400-164SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2682SS | |||
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - (A) Upregulation of ABCA1 & ABCG1 & (B) enhancement of cholesterol efflux by purple Perilla frutescens extracts (PPE) in 50 μg/ml Cu2+-oxidized low-density lipoproteins (LDL)-exposed J774A.1 murine macrophages. (A) For the measurement of ABCA1 & ABCG1 expression, total cell lysates were subjected to western blot analysis with a primary antibody against ABCA1 or ABCG1. beta -actin was used as an internal control. Bar graphs (means ± SEM, n=3) represent quantitative densitometric results of the upper bands. (B) Cholesterol efflux was expressed as the percentage of fluorescence in the medium relative to the total fluorescence. Bar graphs denoted without a common letter indicate significant difference, P<0.05. Image collected & cropped by CiteAb from the following publication (//www.spandidos-publications.com/10.3892/ijmm.2015.2101), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202415382446.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - 6‐Dihydroparadol increases A) ABCA1 & B) ABCG1, but not C) SR‐BI protein levels in cholesterol‐loaded THP‐1‐derived macrophages. THP‐1 cells were differentiated as described in Figure 2, & then loaded with unlabeled cholesterol for 24 h. Cells were treated with increasing concentrations of 6‐dihydroparadol (1–30 μm) for another 24 h. The protein levels of ABCA1, ABCG1, & SR‐B1 were detected by Western blot analysis. The control was treated with solvent vehicle (0.1% DMSO). As a positive control, TO901317 (5 μm, 24 h) was used. The bar graphs represent mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, & ***p < 0.001 versus control (determined by Student's t‐test or ANOVA with Bonferroni's post hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29802792), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202415384115.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Akt inhibition suppresses mTORC1 activity.BHK-ABCA1 cells were induced overnight with mifepristone (10 nM) & then incubated with DEBC, LY294002 or rapamycin at indicated concentrations for 2 h. Cells were then lysed & analyzed for ABCA1 & phosphorylated S6K by Western blotting. Actin was also blotted as loading control. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113789), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-31020241538240.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Reversal of hepatic steatosis by reduction of SREBP-1 levels.(a) Western blotting analysis of SREBP-1 & ABCA1 levels in livers of miR-33+/+Srebf1+/+, miR-33+/+Srebf1+/−, miR-33−/−Srebf1+/+ & miR-33−/−Srebf1+/− mice. Representative western blot images are shown (n=4). Image collected & cropped by CiteAb from following publication (//pubmed.ncbi.nlm.nih.gov/24300912), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202415291985.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - 6‐Dihydroparadol increases A) ABCA1 & B) ABCG1 protein stability. THP‐1 cells were differentiated as described in Figure 2. Then cells were loaded with unlabeled cholesterol & treated with 6‐dihydroparadol (10 μm), or solvent vehicle (0.1% DMSO, control) for 24 h. Cells were lysed at different time points (0, 1, 2, 3, 4, & 6 h) after treatment with the protein synthesis inhibitor cycloheximide (CHX, 100 μm). The protein levels of both ABCA1 & ABCG1 were detected by Western blot analysis. The data points represent mean ± SD from three independent experiments. *p < 0.05 & **p < 0.01 versus control at the same time point (determined by Student's t‐test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29802792), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202415394516.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Ligand activation of LXR inhibits LPS-induced MAP kinase activation through Abca1 induction.(A–D) Bone marrow-derived macrophages from Lxr alpha −/−Lxr beta −/− & control wild-type mice (A, B), or bone marrow-derived macrophages from myeloid-specific Abca1−/− & control wild-type mice (C, D) were pretreated with GW3965 (1 µM) overnight, followed by stimulation with LPS (10 ng/ml) for 20 min or 1 hr. Whole cell lysates were harvested & protein expression was analyzed by immunoblotting with the indicated antibodies (A, C). Protein expression was quantified by Image Quant TL7.0 (B, D). N = 4–6 per group. *p < 0.05, **p < 0.01, NS, not significant. Error bars represent means ± SEM.DOI://dx.doi.org/10.7554/eLife.08009.012 Image collected & cropped by CiteAb from the following publication (//elifesciences.org/articles/08009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202415392521.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - 6‐Dihydroparadol increases A) ABCA1 & B) ABCG1, but not C) SR‐BI protein levels in cholesterol‐loaded THP‐1‐derived macrophages. THP‐1 cells were differentiated as described in Figure 2, & then loaded with unlabeled cholesterol for 24 h. Cells were treated with increasing concentrations of 6‐dihydroparadol (1–30 μm) for another 24 h. The protein levels of ABCA1, ABCG1, & SR‐B1 were detected by Western blot analysis. The control was treated with solvent vehicle (0.1% DMSO). As a positive control, TO901317 (5 μm, 24 h) was used. The bar graphs represent mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, & ***p < 0.001 versus control (determined by Student's t‐test or ANOVA with Bonferroni's post hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29802792), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202415392590.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Western Blotting for ABCA1, as detailed in Supplementary Protocol #5 (Additional file 1). Caco-2 cells cultivated on filter inserts were treated for 48 h with bexarotene (RXR agonist, 5 μM), T0901317 (LXR agonist, 10 μM), GW3965 (LXR agonist, 10 μM) or the vehicle control (DMSO 0.1%). Protein expression was then determined by western blot analysis. Results were normalized for interexperimental variance & then set in relation to the vehicle control. Bar graphs represent mean ± SD from three independent experiments. A representative blot is shown - the bands stem from the same membrane & the vertical line indicates excised irrelevant bands. ns not significant, *P < 0.05, **P < 0.01 versus solvent vehicle (determined by paired t-test) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32308567), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202415284512.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Ligand activation of LXR inhibits LPS-induced MAP kinase activation through Abca1 induction.(A–D) Bone marrow-derived macrophages from Lxr alpha −/−Lxr beta −/− & control wild-type mice (A, B), or bone marrow-derived macrophages from myeloid-specific Abca1−/− & control wild-type mice (C, D) were pretreated with GW3965 (1 µM) overnight, followed by stimulation with LPS (10 ng/ml) for 20 min or 1 hr. Whole cell lysates were harvested & protein expression was analyzed by immunoblotting with the indicated antibodies (A, C). Protein expression was quantified by Image Quant TL7.0 (B, D). N = 4–6 per group. *p < 0.05, **p < 0.01, NS, not significant. Error bars represent means ± SEM.DOI://dx.doi.org/10.7554/eLife.08009.012 Image collected & cropped by CiteAb from the following publication (//elifesciences.org/articles/08009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202415384110.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Ligand activation of LXR inhibits LPS-induced MAP kinase activation through Abca1 induction.(A–D) Bone marrow-derived macrophages from Lxr alpha −/−Lxr beta −/− & control wild-type mice (A, B), or bone marrow-derived macrophages from myeloid-specific Abca1−/− & control wild-type mice (C, D) were pretreated with GW3965 (1 µM) overnight, followed by stimulation with LPS (10 ng/ml) for 20 min or 1 hr. Whole cell lysates were harvested & protein expression was analyzed by immunoblotting with the indicated antibodies (A, C). Protein expression was quantified by Image Quant TL7.0 (B, D). N = 4–6 per group. *p < 0.05, **p < 0.01, NS, not significant. Error bars represent means ± SEM.DOI://dx.doi.org/10.7554/eLife.08009.012 Image collected & cropped by CiteAb from the following publication (//elifesciences.org/articles/08009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-31020241534346.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Expression of ABCA1 & CROT in livers & RIP140 in macrophages is elevated in miR-33−/−Apoe−/− mice compared with miR-33+/+Apoe−/− mice. A, Quantitative real-time PCR analysis of Abca1, Crot, Cpt1a, & Prkaa1in livers from miR-33+/+Apoe−/− & miR-33−/−Apoe−/− mice. Values from miR-33+/+Apoe−/− mice were set at 100%. Values are mean±SE (n=9 to 11each); **P<0.01. B, Western analysis of ABCA1, CROT, CPT1a, & AMPK alpha in livers from miR-33+/+Apoe−/− & miR-33−/−Apoe−/− mice. beta -actin was used as a loading control. C, Densitometry of ABCA1, CROT, CPT1a, & AMPK alpha in livers from miR-33+/+Apoe−/− & miR-33−/−Apoe−/− mice. Values from miR-33+/+Apoe−/− mice were set at 100%. Values are mean±SE (n=4 each); *P<0.05. D, Total cholesterol, free cholesterol, cholesterol ester, & triglyceride levels in livers of miR-33+/+Apoe−/− & miR-33−/−Apoe−/− mice. Values are mean±SE (n=9 to 11 each). E, HE staining of livers of miR-33+/+Apoe−/− & miR-33−/−Apoe−/− mice at age 20 weeks fed NC. Scale bar: 100 μm. F, Quantitative real-time PCR analysis of Nrip1 (RIP140) in peritoneal macrophages from miR-33+/+Apoe−/− & miR-33−/−Apoe−/− mice. Values from miR-33+/+Apoe−/− mice were set at 100%. Values are mean±SE (n=7 each). G, Western analysis of NRIP1 (RIP140) in peritoneal macrophages from miR-33+/+Apoe−/− & miR-33−/−Apoe−/− mice. GAPDH was used as a loading control. H, Densitometry of NRIP1 (RIP140) in peritoneal macrophages from miR-33+/+Apoe−/− & miR-33−/−Apoe−/− mice. Values from miR-33+/+Apoe−/− mice were set at 100%. Values are mean±SE (n=4 each); *P<0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23316322), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-31020241616095.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Basal ABCA1 expression & function in patient-derived iRPEs. (A) Representation of patient-derived iPSC lines & genotypes harboring polymorphisms in ABCA1 that are associated with decreased or increased risk for AMD development. (B) Relative expression of ABCA1 mRNA in patient-derived iRPEs under basal conditions normalized to RPL28 & decreased risk group. (C) Western blot analysis of ABCA1 levels in patient-derived iRPEs under basal conditions. Actin was detected as loading control. ABCA1 expression was quantified & normalized to actin. (D,E) Relative expression of ABCG1 (D) & NR1H3 (E) mRNA in patient-derived iRPEs under basal conditions normalized to RPL28 & decreased risk group. (F) Cholesterol efflux in patient-derived iRPEs after direct cell labeling & in the presence of ApoAI. (G) Cholesterol efflux in patient-derived iRPEs after phagocytosis of BODIPY-cholesterol-loaded POSs & in the presence of ApoAI. (H) Quantification of phagocytosed POSs per nuclei in patient-derived iRPEs. Values shown are means ± SD (n = 3). * p < 0.05; *** p < 0.001. Unpaired Student’s t-test. (I) Representative fluorescence microscopy images of phagocytosed FITC-labeled POSs (green) & staining for ZO-1 (red) & DAPI (blue) of increased risk cell line IPS19-00096. Scale bar = 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35328615), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416171459.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - A–C) Effects of 6‐dihydroparadol & specific proteasomal, lysosomal, & calpain inhibitors on the ABCA1 protein levels. THP‐1 cells were differentiated as described in Figure 2, & then loaded with unlabeled cholesterol for 24 h. Cells were treated with or without 6‐dihydroparadol (6‐DP, 30 μm) for 24 h & incubated for another 3 h with or without the proteasome inhibitor lactacystin (10 μm), the lysosomal inhibitor chloroquine (100 μm), or the calpain inhibitor calpeptin (30 μg mL−1). The ABCA1 protein levels were detected by Western blot analysis. The bar graphs represent mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, & ***p < 0.001 versus control; n.s., not significant versus control (determined by Student's t‐test or ANOVA with Bonferroni's post hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29802792), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416165615.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Suppressive effects of Ucn1 on foam cell formation & related protein expression in human monocyte-derived macrophages.Human monocytes were incubated for 7 days with RPMI-1640 supplemented with 10% human serum & the indicated concentrations of Ucn1, followed by a 19 h-incubation with 50 µg/ml oxLDL in the presence of 0.1 mmol/l [3H]oleate. Intracellular CE accumulation was determined from the radioactivity of cholesterol-[3H]oleate. Otherwise, before the addition of oxLDL, cells were harvested & subjected to immunoblotting analyses for CD36, ACAT1, or ABCA1. beta -Actin served as a loading control. Data are expressed as means ± SEM from 4–6 independent experiments with monocytes from 4–6 different donors. Baseline (1 fold) = 8.4±2.2 nmol/mg cell protein. *P<0.05, †P<0.001 vs. 0 nmol/l of Ucn1. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0110866), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416182616.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Effect of evodiamine on ABCA1 transcription & the degradation rate of ABCA1 protein. (a) Differentiated THP-1 macrophages were incubated with 10 μM evodiamine or 10 μM pioglitazone as positive control for 24 h. Total RNA was extracted & ABCA1 mRNA expression levels were quantified by qRT-PCR. (b) 293 T cells were transfected with a luciferase reporter construct driven by the human ABCA1 promoter as described in the Materials & Methods section. After transfection, cells were treated with 10 μM Evodiamine or 1 μM T0901317 as positive control for 24 h. (c) Differentiated THP-1 macrophages were incubated for 24 h with (black circle) or without (Veh; white circle) evodiamine (10 μM) & lysed after addition of cycloheximide (CHX; 140 μM) at different time points (0, 10, 20, 40 min). Western blot analysis shows the decline of ABCA1 protein level with cycloheximide in the presence & absence of evodiamine. All data are means ± S.D. (n = 3) vs. solvent vehicle control (DMSO), *p < 0.05, **p < 0.01, n.s. no significance (ANOVA/Bonferroni). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30038271), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416173512.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - miR-33 deficiency improved cholesterol efflux in macrophages. A, Quantitative real-time PCR analysis of Abca1 & Abcg1 in macrophages from miR-33+/+Apoe−/− & miR-33−/−Apoe−/− mice. Values from miR-33+/+Apoe−/− were set at 100%. Values are mean±SE (n=7 each); ***P<0.001. B, Western blotting analysis of ABCA1 & ABCG1 in thioglycollate-elicited peritoneal macrophages from miR-33+/+Apoe−/− & miR-33−/−Apoe−/− mice. GAPDH was used as a loading control. C, Cholesterol efflux from thioglycollate-elicited peritoneal macrophages in the presence or absence of apoA-I (5 or 10 μg/mL). Values are mean±SE (n=6 each); **P<0.01. D, Cholesterol efflux from thioglycollate-elicited peritoneal macrophages in the presence or absence of HDL-C (50 or 100 μg/mL). Values are mean±SE (n=6 each); **P<0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23316322), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-31020241616047.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - A–C) Effects of 6‐dihydroparadol & specific proteasomal, lysosomal, & calpain inhibitors on the ABCA1 protein levels. THP‐1 cells were differentiated as described in Figure 2, & then loaded with unlabeled cholesterol for 24 h. Cells were treated with or without 6‐dihydroparadol (6‐DP, 30 μm) for 24 h & incubated for another 3 h with or without the proteasome inhibitor lactacystin (10 μm), the lysosomal inhibitor chloroquine (100 μm), or the calpain inhibitor calpeptin (30 μg mL−1). The ABCA1 protein levels were detected by Western blot analysis. The bar graphs represent mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, & ***p < 0.001 versus control; n.s., not significant versus control (determined by Student's t‐test or ANOVA with Bonferroni's post hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29802792), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416165626.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Srebf1 is a miR-33 target gene.(a) Relative changes in lipid metabolism-related genes in the livers of miR-33−/− mice compared with miR-33+/+ mice fed NC at 16 weeks of age. (n=5–8 each,*P<0.05 in Student’s t-test). (b) Conservation of miR-33 target regions in the 3′UTR of Srebf1. Underlined sequences are the potential binding site of miR-33 seed sequences. * indicates the conservation among spieces. (c) 3′UTR reporter assay used to verify the target. Luciferase reporter activity of human & mouse SREBP-1 gene 3′UTR constructs in 293T cells overexpressing miR-control (miR-Con) & miR-33 (n=4 each, *P<0.05 & ***P<0.001 in Student’s t-test). (d) miR-33 dose-dependent changes in luciferase reporter activity of mouse Srebf1 3′UTR construct in 293T cells. miR-Con & miR-146a is used as a negative control (n=4 each, *P<0.05 & ***P<0.001 in one-way analysis of valiance test). (e) Luciferase reporter activity of the WT or mutant Srebf1 3′UTR at the potential miR-33 binding site in 293T cells (n=4 each, **P<0.01 in Student’s t-test). (f,g) Luciferase reporter activity of SRE-promoter (f) or FAS-promoter (g) in 293T cells. 293T cells were co-transfected with mouse Srebf1 with the full-length 3′UTR or without the 3′UTR, along with expression plasmids for miR-negative control, or miR-33. Values are the mean±s.e. (n=4 each, **P<0.01 versus miR-Con. ***P<0.001 versus miR-Con in one-way analysis of valiance test). (h) Western blotting analysis of SREBP-1, ABCA1, & IRS-2 in miR-33 transduced HepG2 cells & primary hepatocytes & hepatocytes prepared from miR-33+/+ & miR-33−/− mice. Representative western blot images are shown (n=4). Values are the means±s.e.m. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24300912), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416165627.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - (A) Chemical structure, (B) cytotoxicity of alpha -asarone, (C) enhancement of cholesterol efflux by alpha -asarone, (D & E) upregulation of ABCA1 & ABCG1 by alpha -asarone & beta -asarone, & (F) elevation of retinoid X receptor (RXR) alpha transcription. J774A.1 murine macrophages were exposed to 50 μg/ml oxidized low-density lipoprotein (LDL) & treated with 1–10 μM purple Perilla frutescens extracts (PPE)-alpha -asarone & 5–10 μM beta -asarone. (B) MTT assay was performed for the measurement of alpha -asarone toxicity. Graph data represent 1 of 4 independent experiments with multiple estimations. Values are expressed as the percentage cell survival relative to the untreated control cells (cell viability, 100%). (C) Cholesterol efflux was expressed as the percentage fluorescence in the medium relative to total fluorescence. (D & E) For the measurement of ABCA1 & ABCG1 expression, total cell lysates were subjected to western blot analysis with a primary antibody against ABCG1 or ABCG1. beta -actin was used as an internal control. Bar graphs (means ± SEM, n=3) represent quantitative densitometric results of the upper bands. Bar graphs denoted without a common letter indicate significant difference, P<0.05. (F) RXR alpha mRNA expression was measured by RT-PCR. GAPDH was used as a housekeeping gene for the co-amplification with RXR alpha . Image collected & cropped by CiteAb from the following publication (//www.spandidos-publications.com/10.3892/ijmm.2015.2101), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416161846.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Bilirubin significantly decreases expression of ATP‐binding cassette transporter A1 (ABCA1) protein in THP‐1 macrophages treated with LXR agonist (TO901317) to upregulate ABCA1 protein. THP‐1 cells were differentiated for 72 hours with 200 nmol/L phorbol‐12‐myristate‐13‐acetate & then loaded with unlabeled cholesterol for another 24 hours. Cells were treated with TO901317 (5 μmol/L) or solvent vehicle (0.1% dimethyl sulfoxide [DMSO]) for 24 hours. Afterward, cells were treated with bilirubin (17.1 μmol/L) or solvent vehicle (0.1% DMSO) for 16 hours. The protein levels of ABCA1 were detected by western blot analysis. The bar graphs present mean±SD from 3 independent experiments. ***P<0.001 vs control (determined by ANOVA with Bonferroni post hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28455345), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416175272.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Induction of cholesterol efflux attenuates the enhancement in HIV-1infectivity in NPCD55 cells. (A) Normal & NPCD55 cells were treated with 5 μM TO-901317 at 24 h post-infection & cultured for 72 h in the presence of the compound. At 96 h post-infection the cells were harvested & ABCA1, Gag, & beta -actin expression was detected by Western blotting analysis. All samples were loaded on the same gel. (B) AmplexRed assay was performed to measure free cholesterol content of untreated (filled) & TO-901317-treated (slashed) cells. Cholesterol content was normalized to protein concentration. (C) AmplexRed assay was performed to measure virion-associated cholesterol from purified virus produced in untreated (filled) & TO-901317-treated (slashed) infected cells. Virion-associated cholesterol content was normalized to p24 concentration. (D) TZM-bl reporter assay was performed to measure virus infectivity when cholesterol efflux was induced via TO-901317 stimulation. The ρ values were calculated by performing student T-test (*denotes < 0.05). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22273177), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-31020241617529.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Effects of apabetalone on ABCA1 expression & carboplatin response in ovarian cancer cells. (A) Apabetalone treatment reduced expression of ABCA1 in OVCAR-5 & OVCAR-5 CBPR cell lines. Cells were treated for 72 h with control medium (DMSO) or apabetalone (80 µM). Protein extracts from OVCAR-5 (~30 µg) were electrophoresed & immunoblotted with rabbit polyclonal ABCA1 antibody (1/1000, NB400-105, Novus Biological) & beta -actin (1/2000, Abcam) was used as a loading control. (B) Quantification of Western blot. OVCAR-5 (C), CaOV3 (D), OVCAR-5 CBPR (E) & CaOV3 CBPR (F) cell survival following treatment with carboplatin (CBP) alone (0-200 µM, black line) & in combination with apabetalone (Apa, 80 µM, purple line). (G) Carboplatin IC50 for OVCAR-5 & OVCAR-5 CBPR cells ± apabetalone. Data are mean ± SEM from three independent experiments. *P < 0.05, Student’s t-test. (H) Carboplatin IC50 for CaOV3 & CaOV3 CBPR cells ± apabetalone. Data are mean ± SEM from three independent experiments. P < 0.05, Student’s t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35582032), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416161826.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Expression of ATP‐binding cassette transporter A1 (ABCA1) protein in THP‐1 macrophages treated with bilirubin & in peripheral blood mononuclear cells (PBMCs) from Gilbert syndrome (GS) patients. A, Bilirubin suppresses the expression of ABCA1 protein in THP‐1‐derived macrophages time‐dependently. THP‐1 cells were differentiated as described in Figure 1 & then loaded with unlabeled cholesterol for another 24 hours. Cells were treated with bilirubin (17.1 μmol/L) for 4, 8, 16, & 24 hours. The protein levels of ABCA1 were detected by western blotting. Control was treated with solvent vehicle (0.1% dimethyl sulfoxide). The bar graph presents mean±SD from 3 independent experiments. B, Expression of ABCA1 protein is decreased in PBMCs from participants with high bilirubin blood levels (GS) compared with healthy controls. The protein levels of ABCA1 were detected by western blotting. The bar graph presents mean±SEM (n=28 per group). *P<0.05, **P<0.01 & ***P<0.001 vs control. ns indicates not significant (determined by Student t test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28455345), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-31020241616374.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - (A) Time course response of ABCA1 induction by pioglitazone, & (B) enhancement of ABCA1 & (C) peroxisome proliferator-activated receptor gamma (PPAR gamma ) by purple Perilla frutescens extracts (PPE). J774A.1 murine macrophages were incubated with 10 μM pioglitazone & 50 μg/ml oxidized low-density lipoprotein (LDL) in the absence or presence of 1–10 μg/ml PPE. For the measurement of expression of (A & B) ABCA1 & (C) PPAR gamma , total cell lysates were subjected to western blot analysis with a primary antibody against ABCA1 or PPAR gamma . beta -actin was used as an internal control. Bar graphs (means ± SEM, n=3) represent quantitative densitometric results of the upper bands. Bar graphs denoted without a common letter indicate significant difference, P<0.05. Image collected & cropped by CiteAb from the following publication (//www.spandidos-publications.com/10.3892/ijmm.2015.2101), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-3102024161896.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - LXR agonist-stimulated ABCA1 expression & function in patient-derived iRPEs. Patient-derived iRPE lines were stimulated for 16 h with LXR agonist & are relative to unstimulated cells shown in Figure 2. (A) Expression of ABCA1 mRNA normalized to RPL28 & relative to unstimulated cells shown in Figure 2B. (B) Western blot analysis of ABCA1 protein levels. Actin was detected as loading control. ABCA1 expression was quantified & normalized to actin. (C) Cholesterol efflux assay after direct cell labeling & in the presence of ApoAI. (D) Cholesterol efflux assay after phagocytosis of BODIPY-cholesterol-loaded POSs & in the presence of ApoAI. Data are relative to unstimulated cells shown in Figure 2F,G, respectively. Data are presented as means ± SD (n = 3). Unpaired Student’s t-test. * p < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35328615), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416171457.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Akt inhibition by LY294002 or Akt1/2 also enhances cholesterol efflux to apoA-I from ABCA1-expressing BHK cells.A) BHK cells were induced as in Fig. 1 & then incubated with LY294002 (200 µM) for 2 h. Cells were then lysed & analysed for ABCA1, phosphorylated Akt (p-Akt) & total Akt by Western-blotting. Hsp70 was also blotted as loading control. B & C) BHK cells were labeled with [3H] cholesterol & induced with 10 nM mifepristone overnight. Cholesterol efflux was measured after 2 h incubation with BSA (1 mg/ml) or BSA plus apoA-I (5 µg/ml). Some of cells were also incubated with indicated doses of LY294002 (B) or Akt1/2 (C), in addition to apoA-I, during 2 h efflux period. Results are presented as the average of triplicate wells with standard deviation & representative of more than three independent experiments. *** P<0.0001, **P<0.001 & *P<0.05 vs apoA-I only. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113789), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416163770.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Generation, differentiation & analysis of ABCA1-deficient iRPEs. (A) Immunofluorescence staining for ZO-1 (red) in 4-week cultured iRPEs. Nuclei were stained with DAPI (blue). Scale bar = 100 μm. (B) Bright-field microscopy of iRPEs. (C) Ct values of RPE marker genes BEST1, OTX2, RLBP1 & RPE65 in iRPEs & parental iPSCs obtained by qPCR. Values shown are means ± SD (n = 3). Unpaired Student’s t-test. **** p < 0.0001. (D) Sequence alignment of parts of exon 14 (top) & exon 46 (bottom) of ABCA1-deficient iRPE cell clones & parental line. (E) Western blot of ABCA1 protein levels in ABCA1-deficient iRPE cell lines & parental cell line after 16 h of stimulation with 1 μM LXR agonist. Actin was detected as loading control. (F) Relative expression of ABCA1 mRNA in ABCA1-deficient iRPE cell lines & parental cell line normalized to ACTB. Values shown are means ± SD (n = 3). One-way ANOVA with Tukey’s post hoc test. **** p < 0.0001. (G) Relative expression of ABCG1 mRNA in ABCA1-deficient iRPE cell lines & parental cell line normalized to ACTB. Values shown are means ± SD (n = 3). One-way ANOVA with Tukey’s post hoc test. ** p < 0.01; *** p < 0.001. (H) Cholesterol efflux assay in iRPEs in the presence of ApoAI and/or LXR agonist (LXR ag). Values shown are means ± SD (n = 3). Two-way ANOVA with Bonferroni post hoc test vs. DMSO + BSA control. **** p < 0.0001. (I) Bright-field (BF) microscopy & Nile Red fluorescence microscopy (overview & close-up view marked with white squares) of 4-week cultured ABCA1-deficient iRPE cell lines & parental cell line. Relative fluorescence was quantified & is shown as mean ± SD (n = 8). One-way ANOVA with Tukey’s post hoc test. * p < 0.05, **** p < 0.0001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35328615), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416173523.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Akt inhibition enhances cholesterol efflux to apoA-I from wt MEFs, but not from TSC2-/- MEFs where mTORC1 is constitutively activated.A) Mouse embryonic fibroblasts (MEFs), wt & TSC2-/-, were induced overnight with T0901317 (10 µM). Cell lysates were collected for Western blotting for phosphorylated S6K & total S6K. B) wt & TSC2-/- MEFs were incubated with or without T0901317 (10 µM) overnight. Some of cells were then incubated with apoA-I (10 µg/ml) or apoA-I plus DEBC (25 µM) for 2 h. The expression of ABCA1, phosphorylated Akt, total Akt & loading control hsp70 were analyzed by Western blotting. C) wt & TSC2-/- were labeled with [3H] cholesterol for 1 day & then incubated with or without T0901317 (10 µM) overnight. Some of cells were then incubated with apoA-I (10 µg/ml) or apoA-I plus DEBC (25 µM) for 2 h to analyze cholesterol efflux. Data presented as the average of triplicate wells with standard deviation & representative of at least three independent experiments. *** P<0.0001 vs apoA-I only. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113789), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416163724.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Akt inhibition by DEBC enhances cholesterol efflux to apoA-I specifically from ABCA1-expressing BHK cells.A) BHK-ABCA1 cells were induced with mifepristone (10 nM) overnight & then incubated with indicated doses of DEBC for 2 h. Cells were then lysed & Western-blotted for ABCA1, phosphorylated Akt (p-Akt) & total Akt. Hsp70 was also blotted as loading control. B) BHK-ABCA1 cells were labeled with [3H] cholesterol & induced overnight as above. After 2 h incubation with BSA (1 mg/ml) or BSA plus apoA-I (5 µg/ml), cholesterol efflux was measured as described in the Methods section. Some of the cells were also incubated with indicated doses of DEBC, in addition to apoA-I, during 2 h efflux period. C) BHK-ABCA1 & BHK-A937V cells were induced with mifepristone (10 nM) overnight. 2 h Cholesterol efflux was measured as above either with or without DEBC (25 µM). Results are presented as the average of triplicate wells with standard deviation & representative of more than three independent experiments. *** P<0.0001 & **P<0.001 vs apoA-I only. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113789), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416175212.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - LXRs control expression of genes involved in cholesterol homeostasis & fatty acid synthesis in MPECs.(A) qPCR analysis of Abca1, Abcg1 & Idol levels in WT (+/+) & Lxr alpha beta −/− (lxr−/−) MPECs after DMSO (vehicle) or T0901317 stimulation (B) Effect of 9-cis retinoic acid and/or T0901317 stimulation on Abca1 accumulation levels in WT (+/+) & Lxr alpha beta −/− (lxr−/−) MPECs (C) qPCR analysis of Srebp1, Acc, & Fas levels in WT (+/+) & Lxr alpha beta −/− (lxr−/−) MPECs after DMSO (vehicle) or T0901317 stimulation. (qPCR analysis results from 4 independant experiments & was normalized using 36b4 gene). *p<0.05, **p<0.01, ***p<0.001 in Student’s t test. Error bars represent mean ± SEM. (D) Western blot analysis was performed on WT (+/+) or Lxr alpha beta −/− MPECs using Srebp1c, Abca1 & beta -Actin antibodies. (E) Oil-Red O staining (ORO) & Normarski/Dapi of WT (+/+) & Lxr alpha beta −/− MPECs, or WT MEFs, treated for 48h with DMSO (vehicle) or T0901317 (1 µM). Head arrows indicate lipid droplets. Scale bars 100 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23554947), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-31020241616059.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - (A) Time course response of ABCA1 induction by pioglitazone, & (B) enhancement of ABCA1 & (C) peroxisome proliferator-activated receptor gamma (PPAR gamma ) by purple Perilla frutescens extracts (PPE). J774A.1 murine macrophages were incubated with 10 μM pioglitazone & 50 μg/ml oxidized low-density lipoprotein (LDL) in the absence or presence of 1–10 μg/ml PPE. For the measurement of expression of (A & B) ABCA1 & (C) PPAR gamma , total cell lysates were subjected to western blot analysis with a primary antibody against ABCA1 or PPAR gamma . beta -actin was used as an internal control. Bar graphs (means ± SEM, n=3) represent quantitative densitometric results of the upper bands. Bar graphs denoted without a common letter indicate significant difference, P<0.05. Image collected & cropped by CiteAb from the following publication (//www.spandidos-publications.com/10.3892/ijmm.2015.2101), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416171495.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Anti-ApoA-1 IgGs upregulate ABCA1. ABCA1 was increased after 16 & 24 h of anti-ApoA-1 IgG exposure to HMDM at the mRNA level as revealed by RT-PCR (a) as well as at the protein level after 24 h anti-apoA-1 IgG stimulation, as revealed by Western blot analysis (b). In panel a, data are expressed as fold change expression of the mean ± SD of ABCA1 calculated by delta delta CT method of six independent experiments (n = 6) & values were normalized to untreated condition. p-values were calculated using the Student’s t-test: * p < 0.05, ** p < 0.01, **** p < 0.0001. (b) One of four representative Western blots is shown. Data are the mean ± SD of band intensity volume/actin intensity volume of four independent experiments (n = 4). p-values were calculated using the Student’s t-test: * p = 0.02, ** p = 0.005. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31766415), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-31020241616076.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - A–C) Effects of 6‐dihydroparadol & specific proteasomal, lysosomal, & calpain inhibitors on the ABCA1 protein levels. THP‐1 cells were differentiated as described in Figure 2, & then loaded with unlabeled cholesterol for 24 h. Cells were treated with or without 6‐dihydroparadol (6‐DP, 30 μm) for 24 h & incubated for another 3 h with or without the proteasome inhibitor lactacystin (10 μm), the lysosomal inhibitor chloroquine (100 μm), or the calpain inhibitor calpeptin (30 μg mL−1). The ABCA1 protein levels were detected by Western blot analysis. The bar graphs represent mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, & ***p < 0.001 versus control; n.s., not significant versus control (determined by Student's t‐test or ANOVA with Bonferroni's post hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29802792), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-31020241618917.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - ABCA1 protein expression is upregulated in ovarian cancer cells with acquired carboplatin resistance. ABCA1 expression in OVCAR-5 (A) & CaOV3 (C) & carboplatin resistant OVCAR-5 CBPR (B) & CaOV3 CBPR (D) by immunocytochemistry using rabbit polyclonal ABCA1 antibody (1/100, NB400-105, Novus Biological). (E) OVCAR-5 cells with Rabbit IgG & (F) CaOV3 cells with Rabbit IgG. (G) Protein extracts from OVCAR-5 (~30 µg) & CaOV3 cell lines (~60 µg) were electrophoresed & immunoblotted with rabbit polyclonal ABCA1 antibody (1/1000, NB400-105, Novus Biological), & beta -actin (1/2000, Abcam) was used as a loading control. A major band was detected at ~250 kDa, which is the predicted size for ABCA1. (H) Quantitation of ABCA1 Western blots. Data are from 2-4 independent experiments. Statistical significance was determined using the Student’s t-test, *P < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35582032), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416171478.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Evodiamine enhances apo A1-mediated ChE from THP-1 macrophages & increases ABCA1 protein level. (a) Differentiated THP-1 cells were loaded with [3H]-cholesterol together with the indicated treatments for 24 h. On the next day, the cells were washed twice with PBS & incubated with the same compounds [solvent vehicle control (Veh; ≤0.1% DMSO), evodiamine (1–20 μM), & the PPAR gamma agonist pioglitazone (10 μM) as positive control] with or without 10 µg/mL apo A1. Extracellular as well as intracellular radioactivities were quantified with scintillation counter. Differentiated THP-1-derived macrophages were treated with solvent vehicle control (Veh; ≤0.1% DMSO), evodiamine (10 μM), & the PPAR gamma agonist pioglitazone (10 μM) as positive control. After 24 h incubation, the cells were lysed & 20 μg protein was resolved via SDS-PAGE. Immunodetection was performed with antibodies against the indicated proteins, ABCA1 (b), ABCG1 (c), & SR-B1 (d), & visualized by chemiluminescence detection. All experiments were performed at least three times & data are presented as means ± S.D. vs. solvent vehicle control, *p < 0.05, **p < 0.01, ***p < 0.001, n.s. no significance (ANOVA/Bonferroni). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30038271), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416161816.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - A–C) Effects of 6‐dihydroparadol & specific proteasomal, lysosomal, & calpain inhibitors on the ABCA1 protein levels. THP‐1 cells were differentiated as described in Figure 2, & then loaded with unlabeled cholesterol for 24 h. Cells were treated with or without 6‐dihydroparadol (6‐DP, 30 μm) for 24 h & incubated for another 3 h with or without the proteasome inhibitor lactacystin (10 μm), the lysosomal inhibitor chloroquine (100 μm), or the calpain inhibitor calpeptin (30 μg mL−1). The ABCA1 protein levels were detected by Western blot analysis. The bar graphs represent mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, & ***p < 0.001 versus control; n.s., not significant versus control (determined by Student's t‐test or ANOVA with Bonferroni's post hoc test). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29802792), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416161840.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Functional miR-33 responsive elements in the 3′UTR of ATP8B1 & ABCB11A,B. Conserved sequences in the 3′UTR of ATP8B1 & ABCB11 are partially complementary to miR-33. The element in human ATP8B1 is located 1877–1897 nt after the stop codon. The element in ABCB11 overlaps the stop codon in primates, while rodents show a conserved sequence 732–751 nt after the stop codon.C,D. Luciferase assays in HEK293 cells using the whole 3′UTR of human or murine ATP8B1 & ABCB11, or a single copy of the responsive elements (RE) identified above, or mutant responsive elements (RE*; where AATGCA was mutated to GGGTTG to prevent complementarity to the seed sequence of the miRNA), co-transfected with (closed bars) or without (open bars) a vector to overexpress miR-33. In grey, data from empty (negative control) & R33 (positive control containing a 100% match to miR-33) reporter vectors.E,F. Relative mRNA expression of canalicular transporters in primary murine hepatocytes (n = 4 dishes/condition) & human HuH-7 hepatoma cells (n = 3 dishes/condition) transduced 48 h with empty or miR-33 adenovirus.G. Relative protein levels in HuH7 cells transduced with empty or miR-33 adenovirus. Some cells were incubated for 16 h in the presence of FXR:RXR agonists (2 µmol/L GW4064 : 1 µmol/L 9-cis-retinoic acid) to induce ABCB11. Asterisk indicates a non-specific band. Data shown as mean ± SD; **p < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22767443), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-31020241616034.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - (A) Chemical structure, (B) cytotoxicity of alpha -asarone, (C) enhancement of cholesterol efflux by alpha -asarone, (D & E) upregulation of ABCA1 & ABCG1 by alpha -asarone & beta -asarone, & (F) elevation of retinoid X receptor (RXR) alpha transcription. J774A.1 murine macrophages were exposed to 50 μg/ml oxidized low-density lipoprotein (LDL) & treated with 1–10 μM purple Perilla frutescens extracts (PPE)-alpha -asarone & 5–10 μM beta -asarone. (B) MTT assay was performed for the measurement of alpha -asarone toxicity. Graph data represent 1 of 4 independent experiments with multiple estimations. Values are expressed as the percentage cell survival relative to the untreated control cells (cell viability, 100%). (C) Cholesterol efflux was expressed as the percentage fluorescence in the medium relative to total fluorescence. (D & E) For the measurement of ABCA1 & ABCG1 expression, total cell lysates were subjected to western blot analysis with a primary antibody against ABCG1 or ABCG1. beta -actin was used as an internal control. Bar graphs (means ± SEM, n=3) represent quantitative densitometric results of the upper bands. Bar graphs denoted without a common letter indicate significant difference, P<0.05. (F) RXR alpha mRNA expression was measured by RT-PCR. GAPDH was used as a housekeeping gene for the co-amplification with RXR alpha . Image collected & cropped by CiteAb from the following publication (//www.spandidos-publications.com/10.3892/ijmm.2015.2101), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416175262.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - Gas6 treatment enhances expression of LXR alpha & LXR beta & their target genes in BMDM.Mouse BMDM were stimulated with 400 ng/ml Gas6, 1 μM T0901317, 10 ng/ml interferon (IFN)-gamma , 10 ng/ml IL-4, or 100 ng/ml LPS for 4 h (a,b) or 400 ng/ml Gas6 for the indicated times (c–g). (a,b,e) The amounts of the LXR alpha , LXR beta , ABCA1, ABCG1, ApoE, AIM, Arg2, VEGF, YM1, & Arg1 mRNAs were analyzed by real-time PCR & normalized to that of Hprt mRNA. (c,d,f,g) The relative abundances of LXR alpha , LXR beta , ABCA1, ABCG1, ApoE, Aim, Arg2, & VEGF proteins were determined by Western blotting analysis. The relative densitometric intensity was determined for each band & normalized to beta -actin. Data in all bar graphs are means ± SEM of three independent experiments. *P < 0.05 compared with control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27406916), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-310202416175244.jpg)
![Western Blot: ABCA1 Antibody - BSA Free [NB400-105] - (A) Time course response of ABCA1 induction by TO-091317 & (B) upregulation of ABCA1 by purple Perilla frutescens extracts (PPE), & (C) enhancement of liver X receptor (LXR) alpha induction by PPE. J774A.1 murine macrophages were cultured with 1 μM TO-091317 or 50 μg/ml Cu2+-oxidized low-density lipoprotein (LDL) in the absence or presence of 1–10 μg/ml PPE. For the measurement of expression of (A & B) ABCA1 & (C) LXR alpha , total cell lysates were subjected to western blot analysis with a primary antibody against ABCA1 or LXR alpha . beta -actin was used as an internal control. Bar graphs (means ± SEM, n=3) represent quantitative densitometric results of the upper bands. Bar graphs denoted without a common letter indicate significant difference, P<0.05. Image collected & cropped by CiteAb from the following publication (//www.spandidos-publications.com/10.3892/ijmm.2015.2101), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-105_rabbit-polyclonal-abca1-antibody-31020241616565.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody (NB110-89474) at 1ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89474-img0031.jpg "Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody (NB110-89474) at 1ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody conjugated to Alexa Fluor 488 (NB110-89474AF488) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89474-img0028.jpg)
![Western Blot: CD11b Antibody - BSA Free [NB110-89474] - Western Blot detection of CD11b in RAW 264.7 whole cell lysates using [NB110-89474].](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Western-Blot-NB110-89474-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - Staining of mouse pancreas using [NB110-89474] at 1:400 dilution. Nuclei counterstained with 4',6-diamidino-2-phenylindole (DAPI) (blue). ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89474-img0010.jpg)
![Immunohistochemistry: CD11b Antibody - BSA Free [NB110-89474] - Glibenclamide and Abcc8-/- suppress immune cell infiltration in EAE. White matter of lumbar spinal cord sections from WT control (a), untreated pid-30 WT/EAE (b), glibenclamide-treated pid-30 WT/EAE (c), and pid-30 Abcc8-/-/EAE (d) mice, stained with H&E or immunolabeled for CD45 (leucocyte), CD3 (T cells), CD20 (B cells), or CD11b (macrophage/microglia), as indicated; original magnification, x200 (H&E) or x400 (all immunolabelings). eleft panel: percent of quadrants with inflammatory cells on H&E; four mice/group. efour right panels: Quantification of CD-45-, CD3-, CD20-, and CD11b-expressing cells in white matter; four mice/group; ##P < 0.01 with respect to WT control; **P < 0.01, and ***P < 0.001 with respect to WT/EAE; scale bars, 100 um Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/210) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunohistochemistry-NB110-89474-img0024.jpg)
![Flow (Cell Surface): CD11b Antibody - BSA Free [NB110-89474] - Surface staining of CD11b in CT26 colorectal carcinoma tumor model. Using Alexa Fluor 405 conjugated version of the antibody (NB110-89474AF405). Image from verified customer review.](http://images.novusbio.com/fullsize/CD11b-Antibody-BSA-Free-Flow-Cell-Surface-NB110-89474-img0033.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody conjugated to Alexa Fluor 647 (NB110-89474AF647) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89474-img0029.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody conjugated to DyLight 650 (NB110-8947C) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89474-img0030.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - CD11b Antibody [NB110-89474] - CD11b antibody [NB110-89474] was tested in Raw264.7 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with 4',6-diamidino-2-phenylindole (DAPI) (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89474-img0009.jpg)
![Immunohistochemistry: CD11b Antibody - BSA Free [NB110-89474] - Population of CD11b + myeloid progenitor cells differentiate into SMA + stromal cells within tumors and in vitro. Representative image of CD11b + SMA + double positive cells within tumor stroma. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32731354/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD11b Antibody - BSA Free-Immunohistochemistry-NB110-89474-img0034.jpg)
![Immunohistochemistry: CD11b Antibody - BSA Free [NB110-89474] - Immunohistochemical analysis of CD11b in human renal cancer with [NB110-89474] using 3,3'-Diaminobenzidine (DAB) with hematoxylin counterstain.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunohistochemistry-NB110-89474-img0011.jpg)
![Immunohistochemistry-Frozen: CD11b Antibody - BSA Free [NB110-89474] - Immunohistochemical analysis of frozen sections of mouse spleen using [NB110-89474]. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunohistochemistry-Frozen-NB110-89474-img0021.jpg)
![Immunohistochemistry: CD11b Antibody - BSA Free [NB110-89474] - Representative photomicrographs of cross sections of uteri collected from wild type (WT) mice 24 h after intrauterine infusion with 100 ul of vehicle or 100 ug ultrapure LPS from E. coli O111:B4, and Tlr4-/- mice similarly infused intrauterine with vehicle or LPS. Cross sections were stained with haematoxylin and eosin, and immunostained using a CD11b antibody for granulocytes (red) and DAPI for cell nuclei (white), and images collected at 10X magnification sections (C, F, I, L; bars = 200 um). At least 4 sections per animal and at least 4 fields per section were examined. Only WT mice infused with LPS show evidence of inflammation and accumulation of granulocytes in the endometrium. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0012906) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Immunohistochemistry-NB110-89474-img0023.jpg)
![Flow (Cell Surface): CD11b Antibody - BSA Free [NB110-89474] - CD11b Antibody [NB110-89474] - A surface stain was performed on Raw264.7 cells with DyLight 550-conjugated [NB110-89474R] (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 10 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/CD11b-Antibody-BSA-Free-Flow-Cell-Surface-NB110-89474-img0022.jpg)
![Flow (Cell Surface): CD11b Antibody - BSA Free [NB110-89474] - An intracellular stain was performed on THP-1 cells with CD11b NB110-89474 (blue) and a matched isotype control NBP2-24891 (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/CD11b-Antibody-BSA-Free-Flow-Cell-Surface-NB110-89474-img0032.jpg)
![Simple Western: CD11b Antibody - BSA Free [NB110-89474] - Specific band for Cd11b in 1.0 mg/mL of Dentate Gyrus from Rat Brain. [NB110-89474] was used at a dilution of 1:50. This experiment was performed under reducing conditions using the 12-230 kDa separation system. Simple Western image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Simple-Western-NB110-89474-img0012.jpg)
![Dual RNAscope ISH-IHC: CD11b Antibody - BSA Free [NB110-89474] - Formalin-fixed paraffin-embedded tissue sections of human lymph node were probed for CD11b mRNA (ACD RNAScope Probe, catalog #555098; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using Rabbit Polyclonal (Novus Biologicals catalog #NB110-89474) at 1:50 dilution with 1 hour incubation at room temperature followed by incubation with anti-rabbit IgG VisUCyte HRP Polymer Antibody (Catalog # VC003) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to lymphocytes.](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Dual-RNAscope-ISH-IHC-NB110-89474-img0025.jpg)
![Dual RNAscope ISH-IHC: CD11b Antibody - BSA Free [NB110-89474] - CD14 mRNA (red) and CD11b protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human malignant lymph node. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-CD14 and CD11b antibody at 1:200 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNA scope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/CD11b-Antibody---BSA-Free-Dual-RNAscope-ISH-IHC-NB110-89474-img0026.jpg)
![Western Blot: CD11b Antibody - BSA Free [NB110-89474] - Immunodensities of (a) CD11b, (b) GFAP & (c) NF-kappa B (p65) proteins with representative immunoblots in striatum from Munc18-OE (n = 5) & wild-type (n = 5) mice. Bar graphs are ratios of optical densities of our proteins of interest to beta -actin (42 kDa band), expressed as immunoreactivity in percentage of mean value of the WT group (100%). No differences were detected between groups for any of the analyzed proteins. Right panels are representative immunoblots for target proteins & beta -actin which included Munc18-OE (OE) & wild-type (WT) mice samples. The molecular masses were estimated from referenced standards. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25069615), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89474_rabbit-polyclonal-cd11b-antibody-31020241535670.jpg)
![Immunohistochemistry: CD11b Antibody - BSA Free [NB110-89474] - Comparison of Ki-67 or CD11b immunoreactivity of Aldara-treated dorsal skin samples of C57BL/6 mice using OP or MP. Nuclear proliferation marker Ki-67 immunostaining on OP (a) & MP (b) dorsal skin tissue samples at 400x magnification. Dermal dendritic cells were labelled with anti-CD11b antibody on OP (c) & MP samples (d) at 400x magnification. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30842501), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89474_rabbit-polyclonal-cd11b-antibody-310202415384158.jpg)
![Immunohistochemistry: CD11b Antibody - BSA Free [NB110-89474] - Comparison of Ki-67 or CD11b immunoreactivity of Aldara-treated dorsal skin samples of C57BL/6 mice using OP or MP. Nuclear proliferation marker Ki-67 immunostaining on OP (a) & MP (b) dorsal skin tissue samples at 400x magnification. Dermal dendritic cells were labelled with anti-CD11b antibody on OP (c) & MP samples (d) at 400x magnification. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30842501), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89474_rabbit-polyclonal-cd11b-antibody-31020241539450.jpg)
![Western Blot: CD11b Antibody - BSA Free [NB110-89474] - Immunodensities of (a) CD11b, (b) GFAP & (c) NF-kappa B (p65) proteins with representative immunoblots in cerebral cortex from Munc18-OE (n = 5) & wild-type (n = 5) mice. Bar graphs are ratios of optical densities of our proteins of interest to beta -actin (42 kDa band), expressed as immunoreactivity in percentage of the mean value of the WT group (100%). CD11b was significantly decreased in Munc18-OE mice compared to the WT (t = 3.01; P <0.05). No differences between groups were observed in the levels of GFAP or NF-kappa B. Right panels are representative immunoblots for target proteins & beta -actin which included Munc18-OE (OE) & wild-type (WT) mice samples. The molecular masses were estimated from referenced standards. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25069615), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89474_rabbit-polyclonal-cd11b-antibody-310202415394511.jpg)
![Immunocytochemistry/ Immunofluorescence: CD11b Antibody - BSA Free [NB110-89474] - CD11b staining in IMhu. Cells were stained with antibodies against the CD11b surface antigen. (A) Panel A shows positive staining for CD11b & (B) panel B shows nuclear DAPI staining. Magnitude 40×. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31096716), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89474_rabbit-polyclonal-cd11b-antibody-310202415291998.jpg)
![Flow Cytometry: CD45 Antibody (30-F11) [NB100-77417] - Analysis of CD45 (30F11) in freshly isolated mouse (Balb C) splenocytes (1x10^6) were stained with [NB100-77417] at 1:1000 dilution and detected with FITC conjugated donkey anti-rat IgG secondary (orange). Shown with rat IgG isotype control (blue).](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Flow-Cytometry-NB100-77417-img0004.jpg "Flow Cytometry: CD45 Antibody (30-F11) [NB100-77417] - Analysis of CD45 (30F11) in freshly isolated mouse (Balb C) splenocytes (1x10^6) were stained with [NB100-77417] at 1:1000 dilution and detected with FITC conjugated donkey anti-rat IgG secondary (orange). Shown with rat IgG isotype control (blue).")
![Immunohistochemistry-Paraffin: CD45 Antibody (30-F11) [NB100-77417] - Analysis of FFPE section of mouse spleen using rat monoclonal CD45 antibody (30-F11) [NB100-77417] at 1:50 dilution. The antibody generated an expected membrane staining in the red and white pulp spleenocytes of the tested spleen section.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Paraffin-NB100-77417-img0006.jpg)
![Immunohistochemistry-Paraffin: CD45 Antibody (30-F11) [NB100-77417] - Mouse glomeruli stained with CD45 antibody. 4% formaldehyde fixed paraffin sections. EDTA was used for antigen retrieval. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Paraffin-NB100-77417-img0013.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - Analysis of a FFPE embedded tissue section of mouse liver using 1:100 dilution of CD45 antibody (30-F11) [NB100-77417]. The signal was developed using AEC reagent based method with hematoxylin counterstaining.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0003.jpg)
![Immunohistochemistry-Frozen: CD45 Antibody (30-F11) [NB100-77417] - Analysis of a mouse spleen cryosection using CD45 antibody (30-F11) [NB100-77417] at 1:50 dilution. The signal was detected using goat anti-rat Alexa fluor 488 secondary with DAPI counterstaining. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Frozen-NB100-77417-img0008.jpg)
![Immunohistochemistry-Paraffin: CD45 Antibody (30-F11) [NB100-77417] - Staining of a FFPE mouse liver tissue section using 1:100 dilution of CD45 antibody (30-F11) [NB100-77417]. Signal was detected using AF488 conjugated donkey anti-rat secondary antibody at 1:500 dilution. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Paraffin-NB100-77417-img0002.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - Severe apoptosis and pathology in the orally infected heart. Experimental design is as outlined in Fig. 1B. Heart sections from moribund mice were examined with H&E, and immunohistochemistry staining for pan-leukocyte infiltration using an anti-CD45 antibody. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47455-3), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0009.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - Severe apoptosis and pathology in the orally infected heart. Experimental design is as outlined in Fig. 1B. Heart sections from moribund mice were examined with H&E, and immunohistochemistry staining for pan-leukocyte infiltration using an anti-CD45 antibody. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47455-3), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0012.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - VP1-positive infiltrating M2 macrophage and VP1-positive pneumocytes were detectable in the orally infected lung. Adjacent lung sections were examined with H&E and IHC staining for a pan-leukocyte marker CD45. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47455-3), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0011.jpg)
![Western Blot: CD11b/c Antibody - BSA Free [NB110-40766] - Analysis of CD11b/c in Raw 264.7 whole cell lysate.](http://images.novusbio.com/fullsize/CD11b-c-Antibody---BSA-Free-Western-Blot-NB110-40766-img0002.jpg "Western Blot: CD11b/c Antibody - BSA Free [NB110-40766] - Analysis of CD11b/c in Raw 264.7 whole cell lysate.")
![Immunocytochemistry/Immunofluorescence: CD11b/c Antibody - BSA Free [NB110-40766] - CD11 antibody was tested in Raw264.7 cells with FITC (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/CD11b-c-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-40766-img0006.jpg)
![Immunohistochemistry-Frozen: CD11b/c Antibody - BSA Free [NB110-40766] - 10 um Cryosection of murine acute brain slices stained with CD11b/c antibody (1:300 = 3.3 ug/ml) and Alexa Fluor 555 donkey anti rabbit IgG. Antibody shows specific staining, but the background is quite heavy. Image from verified customer review.](http://images.novusbio.com/fullsize/CD11b-c-Antibody---BSA-Free-Immunohistochemistry-Frozen-NB110-40766-img0009.jpg)
![Flow Cytometry: CD11b/c Antibody - BSA Free [NB110-40766] - A surface stain was performed on RAW 264.7 with NB110-40766 and a matched isotype control. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, DyLight 550.](http://images.novusbio.com/fullsize/CD11b-c-Antibody---BSA-Free-Flow-Cytometry-NB110-40766-img0008.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: CD11b/c Antibody - BSA Free [NB110-40766] - Effects of oltipraz on the expression of CD11b/c, phosphoinositide 3-kinase (PI3K), phosphorylated protein kinase B (p-Akt), and phosphorylated inhibitor of kB alpha (p-IkB alpha) in the spinal cord of the CCI-injured mice. The relative protein levels of (A) CD11b/c and (B) PI3K on the ipsilateral side of the spinal cord in the CCI-injured mice treated with oltipraz (OLT) or vehicle are represented. (C) Representative examples of blots for CD11b/c (160 kDa), PI3K (130 kDa), and GAPDH (37 kDa). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31234342/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD11b-c Antibody - BSA Free-Western Blot-NB110-40766-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b/c Antibody - BSA Free [NB110-40766] - Phase contrast microscopy images of HFA and brain tumor cells and immunofluorescence images of cultured primary brain tumor cells, AA and HFA. HFA were derived from three different fetal brains. HFA from an 18-week- old fetus (passaged once) - GFAP (DAKO) merged with DAPI and CD68 (zoomed: 2.1x magnification); GFAP (green and red) was used as an astrocyte marker and CD68 (red) and CD11b (green) were used as markers for microglia. Nuclei indicated by DAPI (blue) in all images. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0112945), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD11b-c-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-40766-img0010.jpg)
![Immunohistochemistry: CD11b/c Antibody - BSA Free [NB110-40766] - Staining of human bone marrow, myeloid precursors.](http://images.novusbio.com/fullsize/CD11b-c-Antibody---BSA-Free-Immunohistochemistry-NB110-40766-img0007.jpg)
![Western Blot: CD11b/c Antibody - BSA Free [NB110-40766] - Effects of oltipraz on the expression of CD11b/c, phosphoinositide 3-kinase (PI3K), phosphorylated protein kinase B (p-Akt), & phosphorylated inhibitor of kappa B alpha (p-IkB alpha ) in the spinal cord of the CCI-injured mice. The relative protein levels of (A) CD11b/c, (B) PI3K, (D) p-Akt, & (E) p-IKB alpha on the ipsilateral side of the spinal cord in the CCI-injured mice treated with oltipraz (OLT) or vehicle are represented. The sham-operated mice (SHAM) treated with vehicle were used as controls. (C) Representative examples of blots for CD11b/c (160 kDa), PI3K (130 kDa), & GAPDH (37 kDa), & (F) for p-Akt (60 kDa), Akt (60 kDa), p-IKB alpha (40 kDa) & IKB alpha (40 kDa). CD11b/c & PI3K are expressed relative to GAPDH levels whereas phosphorylated proteins are expressed relative to their corresponding total proteins. In all panels, * denotes significant differences vs. sham-operated mice treated with vehicle (p < 0.05; one-way ANOVA followed by the SNK test). Results are presented as the mean ± SEM; n = 5 samples per experimental group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31234342), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-40766_rabbit-polyclonal-cd11b-c-antibody-310202416235533.jpg)
![Western Blot: CD11b/c Antibody - BSA Free [NB110-40766] - Effects of oltipraz on the expression of CD11b/c, PI3K, p-Akt, & p-IkB alpha in the prefrontal cortex of the CCI-injured mice. The relative protein levels of (A) CD11b/c, (B) PI3K, (D) p-Akt, & (E) p-IKB alpha in the prefrontal cortex of the CCI-injured mice treated with oltipraz (OLT) or vehicle. The sham-operated mice (SHAM) treated with vehicle were used as controls. Representative examples of blots for (C) CD11b/c (160 kDa), PI3K (130 kDa) & GAPDH (37 kDa), & for (F) p-Akt (60 kDa), Akt (60 kDa), p-IKB alpha (40 kDa) & IKB alpha (40 kDa). CD11b/c & PI3K are expressed relative to GAPDH levels whereas phosphorylated proteins are expressed relative to their corresponding total proteins. In all panels, * denotes significant differences vs. sham-operated mice treated with vehicle (p < 0.05; one-way ANOVA followed by the SNK test). Results are presented as the mean ± SEM; n = 4-–5 samples per experimental group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31234342), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-40766_rabbit-polyclonal-cd11b-c-antibody-310202416235518.jpg)
![Western Blot: CD11b/c Antibody - BSA Free [NB110-40766] - Effects of oltipraz on the expression of CD11b/c, PI3K, p-Akt, & p-IkB alpha in the hippocampus of the CCI-injured mice. The relative protein levels of (A) CD11b/c, (B) PI3K, (D) p-Akt, & (E) p-IKB alpha in the hippocampus of the CCI-injured mice treated with oltipraz (OLT) or vehicle. The sham-operated mice (SHAM) treated with vehicle were used as controls. Representative examples of blots for (C) CD11b/c (160 kDa), PI3K (130 kDa), & GAPDH (37 kDa); & (F) for p-Akt (60 kDa), Akt (60 kDa), p-IKB alpha (40 kDa), & IKB alpha (40 kDa). CD11b/c & PI3K are expressed relative to GAPDH levels whereas phosphorylated proteins are expressed relative to their corresponding total proteins. In all panels, * denotes significant differences vs. sham-operated mice treated with vehicle (p < 0.05; one-way ANOVA followed by the SNK test). Results are presented as the mean ± SEM; n = 5 samples per experimental group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31234342), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-40766_rabbit-polyclonal-cd11b-c-antibody-310202416235538.jpg)
![Immunocytochemistry/ Immunofluorescence: CD11b/c Antibody - BSA Free [NB110-40766] - Phase contrast microscopy images of HFA & brain tumor cells & immunofluorescence images of cultured primary brain tumor cells, AA & HFA.HFA were derived from three different foetal brains. (A) 18-week foetus (10× magnification); (B) 19-week foetus, first week in culture (10× magnification); (C) 19-week foetus, day 5 in culture (20× magnification); (D) Primary GBM after 2 trypsinisations (20x); (E) Recurrent GBM (20x); (F) Secondary GBM after 3 trypsinisations (10x); (G) OII 14 days in culture (10x); (H) AII 13 days in culture (10x); (I) Negative control for NGS merged with DAPI; (J) Negative control for secondary antibodies merged with DAPI; (K) GBM cells derived from one patient – GFAP (DAKO) merged with DAPI & CD68 (zoomed: 2.4× magnification); (L) primary brain tumor cells from one patient (male, 40 years old) (passaged three times) - GFAP (Novocastra) merged with DAPI; (K & L) GFAP (green) was used as a GBM marker & CD68 (red) was used as a marker for microglia. (M) AA from one Female, 61 years old; (passaged twice) - GFAP (Novocastra) merged with DAPI; (N) AA from one male 40 years old; (passaged once) - GFAP (Sigma) merged with DAPI & CD68 (Abcam); (M & N) GFAP (green) was used as an astrocyte marker & CD68 (red) & CD11b (green) were used as markers for microglia; (O) HFA from one 17-week- old foetus (passaged once) - GFAP (Novocastra) merged with DAPI & CD11b (Novus); (P) HFA from an 18-week- old foetus (passaged once) - GFAP (DAKO) merged with DAPI & CD68 (zoomed: 2.1× magnification); (O & P) GFAP (green & red) was used as an astrocyte marker & CD68 (red) & CD11b (green) were used as markers for microglia. Nuclei indicated by DAPI (blue) in all images. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0112945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-40766_rabbit-polyclonal-cd11b-c-antibody-310202416235543.jpg)
![Western Blot: OCT4 Antibody [NB100-2379] - YM155 significantly reduced tumorsphere formation and inhibited EGFR autophosphorylation and G9a expression. YM155 is reported to suppress cancer stemness; therefore, we used this compound to investigate the cellular mechanism of tumorsphere formation. To compare the cytotoxic capacity of YM155 against tumorsphere formation and parental cell lines, YM155 was applied to HCC827 and A549 cells in the stemness cultured or integrated medium. (F) Moreover, YM155 inhibited EGFR autophosphorylation in A549-derived tumorspheres and reduced Oct4 expression. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0182149) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/OCT4-Antibody-Western-Blot-NB100-2379-img0014.jpg "Western Blot: OCT4 Antibody [NB100-2379] - YM155 significantly reduced tumorsphere formation and inhibited EGFR autophosphorylation and G9a expression. YM155 is reported to suppress cancer stemness; therefore, we used this compound to investigate the cellular mechanism of tumorsphere formation. To compare the cytotoxic capacity of YM155 against tumorsphere formation and parental cell lines, YM155 was applied to HCC827 and A549 cells in the stemness cultured or integrated medium. (F) Moreover, YM155 inhibited EGFR autophosphorylation in A549-derived tumorspheres and reduced Oct4 expression. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0182149) licensed under a CC-BY license.")
![Western Blot: OCT4 Antibody [NB100-2379] - WB detection of OCT4 in mouse brain lysate using OCT4 antibody with ECL based detection. The antibody generated a specific band of OCT4 at the expected ~40kDa position.](http://images.novusbio.com/fullsize/OCT4-Antibody-Western-Blot-NB100-2379-img0011.jpg)
![Flow Cytometry: OCT4 Antibody [NB100-2379] - An intracellular stain was performed on Jurkat with NB100-2379 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody.](http://images.novusbio.com/fullsize/OCT4-Antibody-Flow-Cytometry-NB100-2379-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: OCT4 Antibody [NB100-2379] - Ntera2 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NB100-2379 at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/OCT4-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2379-img0018.jpg)
![Western Blot: OCT4 Antibody [NB100-2379] - MDA-MB-231 subclones transfected with NTC or HIF-1 alpha shRNA vector were treated with vehicle (V) or paclitaxel (P) and Western blot assay was performed. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/OCT4-Antibody-Western-Blot-NB100-2379-img0016.jpg)
![Immunohistochemistry-Paraffin: OCT4 Antibody [NB100-2379] - Analysis of a FFPE tissue section of mouse brain using 1:200 dilution of OCT4 antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/OCT4-Antibody-Immunohistochemistry-Paraffin-NB100-2379-img0017.jpg)
![Flow Cytometry: OCT4 Antibody - BSA Free [NB100-2379] - An intracellular stain was performed on U2-OS cells with OCT4 NB100-2379AF647 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/OCT4-Antibody---BSA-Free-Flow-Cytometry-NB100-2379-img0022.jpg)
![Western Blot: OCT4 Antibody [NB100-2379] - The expression of pluripotency factors Oct4 in human head and neck cancer cell lines.](http://images.novusbio.com/fullsize/OCT4-Antibody-Western-Blot-NB100-2379-img0013.jpg)
![Flow Cytometry: OCT4 Antibody [NB100-2379] - An intracellular stain was performed on Jurkat cells with OCT4 Antibody NB100-2379 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/OCT4-Antibody-Flow-Cytometry-NB100-2379-img0019.jpg)
![Flow Cytometry: OCT4 Antibody [NB100-2379] - An intracellular stain was performed on Neuro2a cells with OCT4 Antibody NB100-2379 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/OCT4-Antibody-Flow-Cytometry-NB100-2379-img0020.jpg)
![Flow Cytometry: OCT4 Antibody [NB100-2379] - An intracellular stain was performed on Ntera2 cells with OCT4 Antibody NB100-2379 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/OCT4-Antibody-Flow-Cytometry-NB100-2379-img0021.jpg)
![Western Blot: OCT4 Antibody - BSA Free [NB100-2379] - Protein expression of NANOG a, OCT4 b & SOX2 c in bovine uterine tissues obtained from control cows & from cows with adenomyosis. Data were normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Bars represent the mean ± SEM. There were no statistical differences between uterine normal & adenomyotic tissues (P > 0.05), as determined by Student’s t-test. Representative blots for NANOG, OCT4, SOX2 & GAPDH are shown below the graphs d. MM – molecular weight marker, C – tissues obtained from control cows, ADENO – tissues obtained from cows with adenomyosis Image collected & cropped by CiteAb from the following publication (//www.rbej.com/content/13/1/110), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2379_rabbit-polyclonal-oct4-antibody-310202415394524.jpg)
![Western Blot: OCT4 Antibody - BSA Free [NB100-2379] - Protein expression of pluripotency markers in uterine cells isolated from control cows & from cows with adenomyosis. NANOG a OCT4 b & SOX2 c protein expression in uterine stromal cells. NANOG d OCT4 e & SOX2 f protein expression in uterine myometrial cells. Data were normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Bars represent the mean ± SEM. Asterisks indicate statistical differences between uterine normal & adenomyotic tissue (*P < 0.05; **P < 0.01), as determined by Student’s t-test. Representative blots for NANOG, OCT4, SOX2 & GAPDH are shown below the graphs g. MM – molecular weight marker, C – cells obtained from control cows, ADENO – cells obtained from cows with adenomyosis Image collected & cropped by CiteAb from the following publication (//www.rbej.com/content/13/1/110), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2379_rabbit-polyclonal-oct4-antibody-310202415384144.jpg)
![Immunohistochemistry: Olig2 Antibody [NBP1-28667] - Mouse cerebral microslice section (coronal, P14) was co-immunostained with anti-Olig2 and anti-NeuN antibodies. Green: Olig2, Red: NeuN. Anti-Olig2 was used at a 1:800 dilution. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/Olig2-Antibody-Immunohistochemistry-NBP1-28667-img0005.jpg "Immunohistochemistry: Olig2 Antibody [NBP1-28667] - Mouse cerebral microslice section (coronal, P14) was co-immunostained with anti-Olig2 and anti-NeuN antibodies. Green: Olig2, Red: NeuN. Anti-Olig2 was used at a 1:800 dilution. This image was submitted via customer Review.")
![Immunocytochemistry/Immunofluorescence: Olig2 Antibody [NBP1-28667] - Rat cortical neuroepithelial cells with anti-Olig2 (red). The cells were treated with basic FGF for 30 hours prior to staining (this induces Olig2 expression in these primary cells).](http://images.novusbio.com/fullsize/Olig2-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-28667-img0004.jpg)
![Immunohistochemistry-Frozen: Olig2 Antibody [NBP1-28667] - Mouse brain cortex. Antibody at 1:300. Purple: Olig2. Green: CD31. Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Olig2-Antibody-Immunohistochemistry-Frozen-NBP1-28667-img0006.jpg)
![Immunohistochemistry: CD11b Antibody (M1/70.15) [NB600-1327] - Immunohistochemical analysis of frozen lymph node section using CD11b Antibody (M1/70.15) [NB600-1327] followed by staining with HRP-conjugated secondary antibody.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunohistochemistry-NB600-1327-img0012.jpg "Immunohistochemistry: CD11b Antibody (M1/70.15) [NB600-1327] - Immunohistochemical analysis of frozen lymph node section using CD11b Antibody (M1/70.15) [NB600-1327] followed by staining with HRP-conjugated secondary antibody.")
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) [NB600-1327] - Characterization of microglia cultures by multiple staining with CD11b Antibody (M1/70.15) [NB600-1327] (panels a. & c.) and anti GFAP (panels b & d). Nuclei appear blue due to 4',6-diamidino-2-phenylindole (DAPI) counter staining.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunocytochemistry-Immunofluorescence-NB600-1327-img0013.jpg)
![Flow Cytometry: CD11b Antibody (M1/70.15) [NB600-1327] - A surface stain was performed on Raw264.7 cells with CD11b (M1/70.15) Antibody [NB600-1327R] (blue) and a matched isotype control (orange), both conjugated to DyLight 550. Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Flow-Cytometry-NB600-1327-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) - BSA Free [NB600-1327] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody [M1/70.15] (NB600-1327) at 1ug/ml overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-BSA-Free-Immunocytochemistry-Immunofluorescence-NB600-1327-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) - BSA Free [NB600-1327] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody [M1/70.15] conjugated to Alexa Fluor 488 (NB600-1327AF488) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-BSA-Free-Immunocytochemistry-Immunofluorescence-NB600-1327-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) [NB600-1327] - Immunocytochemistry/Immunofluorescence (ICC/IF) analysis of RAW264.7 cells using CD11b antibody (M1/70.15) [NB600-1327] with Dylight 488 conjugated secondary (green). Nuclei and tubulin were stained with 4',6-diamidino-2-phenylindole (DAPI) (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunocytochemistry-Immunofluorescence-NB600-1327-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) [NB600-1327] - Immunocytochemical/Immunofluorescent staining in untreated and treated mouse microglia cells using CD11b Antibody (M1/70.15) [NB600-1327]. Image from a verified customer review.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunocytochemistry-Immunofluorescence-NB600-1327-img0015.jpg)
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) [NB600-1327] - Immunocytochemical/Immunofluorescent analysis in mouse primary microglia. Cells were treated with lysophosphatidic acid (LPA) or LPA and an LPAR5 inhibitor in order to investigate the expression of iNOS after 24 hours. CD11b Antibody (M1/70.15) [NB600-1327] was used in a dilution 1:100 in order to stain primary murine microglia. Cy2 (green) and Cy3 (red) were used as secondary antibodies.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunocytochemistry-Immunofluorescence-NB600-1327-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) - BSA Free [NB600-1327] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody [M1/70.15] conjugated to Alexa Fluor 647 (NB600-1327AF647) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-BSA-Free-Immunocytochemistry-Immunofluorescence-NB600-1327-img0019.jpg)
![Flow Cytometry: CD11b Antibody (M1/70.15) [NB600-1327] - Staining of mouse peritoneal macrophages with Rat anti Mouse CD11b Antibody (M1/70.15) [NB600-1327].](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Flow-Cytometry-NB600-1327-img0004.jpg)
![Flow Cytometry: CD11b Antibody (M1/70.15) [NB600-1327] - Staining of mouse peritoneal macrophages with Rat anti Mouse CD11b Antibody (M1/70.15) [NB600-1327]: RPE - Alexa Fluor 750](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Flow-Cytometry-NB600-1327-img0007.jpg)
![Flow Cytometry: CD11b Antibody (M1/70.15) [NB600-1327] - Staining of mouse peritoneal macrophages using the Alexa Fluor (R) 488 conjugate of CD11b Antibody (M1/70.15) [NB600-1327AF488].](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Flow-Cytometry-NB600-1327-img0014.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using Alexa Fluor (R) 488 conjugate of CD45 antibody (OX-1). Rat Splenocytes were stained with CD45 antibody (OX-1) [NB100-64895] (blue) and a matched isotype control [NBP2-27287] (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0005.jpg "Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using Alexa Fluor (R) 488 conjugate of CD45 antibody (OX-1). Rat Splenocytes were stained with CD45 antibody (OX-1) [NB100-64895] (blue) and a matched isotype control [NBP2-27287] (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.")
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using the FITC conjugate of CD45 antibody (OX-1). Staining of rat spleen cells.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0004.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) - BSA Free [NB100-64895] - Representative sequential gating during flow cytometry analysis of rat non-parenchymal liver cells (n = 4). Cells were labeled with antibodies to SE-1 (NB110-68095AF488), CD31, and CD45 (NB100-64895PE). LSECs were then identified as SE-1-Alexa488+ cells (e), and the biexponential CD45-PE/CD31-APC of events (f) were used to display and select the CD45+ CD31+ subsets of LSECs. FMOs (used for gating), and single antibody staining controls are shown in Additional file. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33246411/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-BSA-Free-Flow-Cytometry-NB100-64895-img0006.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Staining of rat peripheral blood lymphocytes with mouse anti-rat CD45 antibody (OX-1) [NB100-64895].](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0001.jpg)
![Western Blot: ABCA1 Antibody (HJ1) [NB100-2068] - Detection of ABCA1 in wildtype liver tissue (in RIPA) Lane 1: KO mouse liver tissue. Lane 2: WT mouse liver tissue.](http://images.novusbio.com/fullsize/ABCA1-Antibody-HJ1-Western-Blot-NB100-2068-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: ABCA1 Antibody (HJ1) [NB100-2068] - Detection of ABCA1 in wildtype liver tissue (in RIPA) Lane 1: KO mouse liver tissue. Lane 2: WT mouse liver tissue.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: ABCA1 Antibody (HJ1) [NB100-2068] - Analysis of ABCA1 in human renal cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/ABCA1-Antibody-HJ1-Immunohistochemistry-NB100-2068-img0006.jpg)
![Flow Cytometry: ABCA1 Antibody (HJ1) [NB100-2068] - Staining of 1 x 10^6 CHO (A) and HEK-293 (B) cells using ABCA1 antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/ABCA1-Antibody-HJ1-Flow-Cytometry-NB100-2068-img0010.jpg)
![Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Western blot analysis of lipid transporters in macrophages treated with or without oxLDL using antibodies against ABCA1 (NB400-164), SR-B1 (NB400-104), and CD36 (NB400-144) . Lrp1Y63F impairs Abca1-mediated cholesterol efflux and increases lipid accumulation in macrophages. Image collected and cropped by CiteAb from the following publication (//elifesciences.org/articles/29292) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ABCA1-Antibody-3A1-891-3-Western-Blot-NB400-164-img0008.jpg "<b>Biological Strategies Validation. </b>Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Western blot analysis of lipid transporters in macrophages treated with or without oxLDL using antibodies against ABCA1 (NB400-164), SR-B1 (NB400-104), and CD36 (NB400-144) . Lrp1Y63F impairs Abca1-mediated cholesterol efflux and increases lipid accumulation in macrophages. Image collected and cropped by CiteAb from the following publication (//elifesciences.org/articles/29292) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: ABCA1 Antibody (3A1.891.3) [NB400-164] - Analysis of FFPE mouse liver using ABCA1 antibody at 1:500 on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Plasma membrane staining was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/ABCA1-Antibody-3A1-891-3-Immunohistochemistry-Paraffin-NB400-164-img0007.jpg)
![Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Detection of ABCA1 using NB400-164 at various dilutions in ABCA1 transfected HeLa lysates.](http://images.novusbio.com/fullsize/ABCA1-Antibody-3A1-891-3-Western-Blot-NB400-164-img0004.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Analysis of ABCA1 in (A) T09 treated RAW 264.7 cells and (B) untreated RAW 264.7 cells.](http://images.novusbio.com/fullsize/ABCA1-Antibody-3A1-891-3-Western-Blot-NB400-164-img0006.jpg)
![Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Lrp1Y63F mutation downregulates hepatic Abca1 levels.(A) Western blot analysis of Abca1 expression in the liver from Lrp1Y63F;Ldlr−/− & Ldlr−/− mice fed with HCHF diet for 16 weeks (n = 5, each group). (B) Western blot analysis of Abca1 expression in the liver from 16 week HCHF-fed Lrp1Y63F;Ldlr−/− & Ldlr−/− mice after BMT (n = 5, each group). All data are mean ±SEM. **p<0.01. Image collected & cropped by CiteAb from the following publication (//elifesciences.org/articles/29292), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-164_rat-monoclonal-abca1-antibody-3a1-891-3-31020241535616.jpg)
![Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Lrp1Y63F mutation has no effect on atherogenic signaling pathways & morphological phenotype in SMCs.(A) Left: representative images of H&E stained descending thoracic aortas (scale bar = 50 μm). Right: aortic wall thickness & cell number were quantified for the indicated genotypes. Data are expressed mean ±SEM; n = 3 per group & genotype. (B) HCHF diet in Lrp1Y63F;Ldlr−/− mice has no effect on PDGF & TGF beta -mediated signaling in the aorta. Proteins were extracted from whole aorta in Lrp1Y63F;Ldlr−/− & Ldlr−/− mice fed with indicated diets. Expression of proteins involved in PDGF signaling pathways was determined by Western blot analysis. (C) Lrp1Y63F mutation did not affect atherogenic signaling pathways mediated by PDGF in vitro. Primary SMCs from WT & Lrp1Y63F mice were incubated with or without 10 ng/ml PDGF-BB for 10 min. Expression of proteins involved in PDGF signaling were determined by Western blot analysis. (D) Lrp1Y63F mutation did not alter SMC functions in vitro. Primary cultured SMCs from WT & Lrp1Y63F mice were incubated with or without 10 ng/ml PDGF-BB under indicated conditions, then cell migration (left) & proliferation (right) were determined. Values from three independent experiments are expressed as mean ±SEM. *p<0.05. Image collected & cropped by CiteAb from the following publication (//elifesciences.org/articles/29292), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-164_rat-monoclonal-abca1-antibody-3a1-891-3-310202416175236.jpg)
![Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Lrp1Y63F impairs Abca1 induction through inhibiting the PPAR gamma /LXR pathway.(A) Real-time PCR analysis of Abca1, Abca7, Pparg, Nr1h3 & Nr2h2 expression in macrophages treated with or without ox-LDL. (B–E) Isolated peritoneal macrophages from Lrp1Y63F;Ldlr−/− & Ldlr−/− were pre-incubated for 1 hr with (B) T0070907 (PPAR gamma antagonist, 10 μM), (C) Rosiglitizone (PPAR gamma agonist) at indicated concentrations in μM, (D) T0901317 (nonspecific LXR agonist) at indicated concentrations in μM, (E) LXR623 (LXR beta full agonist & LXR alpha partial agonist) at indicated concentrations in μM, followed by the treatment with or without oxLDL for an additional 24 hr. Abca1 expression was assessed by immunoblot analysis (left). Protein expression was quantified & analyzed (right). Data are mean ±SEM from three independent experiments. *p<0.05; **p<0.01. Image collected & cropped by CiteAb from the following publication (//elifesciences.org/articles/29292), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-164_rat-monoclonal-abca1-antibody-3a1-891-3-310202416154639.jpg)
![Western Blot: ABCA1 Antibody (3A1.891.3) [NB400-164] - Lrp1Y63F mutation has no effect on atherogenic signaling pathways & morphological phenotype in SMCs.(A) Left: representative images of H&E stained descending thoracic aortas (scale bar = 50 μm). Right: aortic wall thickness & cell number were quantified for the indicated genotypes. Data are expressed mean ±SEM; n = 3 per group & genotype. (B) HCHF diet in Lrp1Y63F;Ldlr−/− mice has no effect on PDGF & TGF beta -mediated signaling in the aorta. Proteins were extracted from whole aorta in Lrp1Y63F;Ldlr−/− & Ldlr−/− mice fed with indicated diets. Expression of proteins involved in PDGF signaling pathways was determined by Western blot analysis. (C) Lrp1Y63F mutation did not affect atherogenic signaling pathways mediated by PDGF in vitro. Primary SMCs from WT & Lrp1Y63F mice were incubated with or without 10 ng/ml PDGF-BB for 10 min. Expression of proteins involved in PDGF signaling were determined by Western blot analysis. (D) Lrp1Y63F mutation did not alter SMC functions in vitro. Primary cultured SMCs from WT & Lrp1Y63F mice were incubated with or without 10 ng/ml PDGF-BB under indicated conditions, then cell migration (left) & proliferation (right) were determined. Values from three independent experiments are expressed as mean ±SEM. *p<0.05. Image collected & cropped by CiteAb from the following publication (//elifesciences.org/articles/29292), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-164_rat-monoclonal-abca1-antibody-3a1-891-3-31020241616063.jpg)
![Western Blot: L1CAM Antibody (UJ127.11) [NB100-2682] - SUM159 cells were exposed to 20% or 1% O2 for 48 hours, whole cell lysates were loaded with 50 ug/lane. 10% SDS-PAGE. L1CAM Antibody (NB100-2682) primary antibody: 1:1000, 4C, overnight. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Western-Blot-NB100-2682-img0006.jpg "Western Blot: L1CAM Antibody (UJ127.11) [NB100-2682] - SUM159 cells were exposed to 20% or 1% O2 for 48 hours, whole cell lysates were loaded with 50 ug/lane. 10% SDS-PAGE. L1CAM Antibody (NB100-2682) primary antibody: 1:1000, 4C, overnight. Western blot image submitted by a verified customer review.")
![Immunocytochemistry/Immunofluorescence: L1CAM Antibody (UJ127.11) [NB100-2682] - The left panel (A) shows untreated Neuro2a cells and the right panel (B) shows Neuro2a cells that were serum starved then treated with 1mM cAMP overnight to induce axon growth. Cells were fixed in 4% paraformaldehyde for 10 minutes and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti- NB100-2682 at 5 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Immunocytochemistry-Immunofluorescence-NB100-2682-img0005.jpg)
![Immunohistochemistry-Frozen: L1CAM Antibody (UJ127.11) [NB100-2682] - Human pancreatic ductal adenocarcinoma (PDAC) tissue section stained with L1CAM antibody. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Immunohistochemistry-Frozen-NB100-2682-img0007.jpg)
![Flow Cytometry: L1CAM Antibody (UJ127.11) [NB100-2682] - A surface stain was performed on HeLa cells with L1CAM Antibody (UJ127.11) NB100-2682 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 20 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Flow-Cytometry-NB100-2682-img0001.jpg)
![Western Blot: L1CAM Antibody (UJ127.11) [NB100-2682] - Total protein from human HeLa, A431 and SHSY-5Y cell lines and human Brain was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-L1CAM (NB100-2682) in blocking buffer and detected with an anti-mouse HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Western-Blot-NB100-2682-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: L1CAM Antibody (UJ127.11) [NB100-2682] - The left panel (A) shows untreated Neuro2a cells and the right panel (B) shows Neuro2a cells that were serum starved then treated with 1mM cAMP overnight to induce axon growth. Cells were fixed in 4% paraformaldehyde for 10 minutes and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti- NB100-2682 at 5 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Immunocytochemistry-Immunofluorescence-NB100-2682-img0004.jpg)
![Immunohistochemistry-Paraffin: L1CAM Antibody (UJ127.11) [NB100-2682] - Analysis of a FFPE tissue section of human brain using 1:200 dilution of L1CAM [UJ127.11] antibody. The staining was developed using HRP labeled anti-mouse secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin. Cytoplasmic and membrane staining as observed in the cerebral cortex](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Immunohistochemistry-Paraffin-NB100-2682-img0003.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood lymphocytes with anti-human CD45 antibody (MEM-28) Alexa Fluor 700.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0021.jpg "Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood lymphocytes with anti-human CD45 antibody (MEM-28) Alexa Fluor 700.")
![Immunocytochemistry/Immunofluorescence: CD45 Antibody (MEM-28) [NB500-319] - staining of human peripheral blood mononuclear cell using anti-human CD45 antibody (MEM-28) (green). DNA visualized by DAPI (blue).](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Immunocytochemistry-NB500-319-img0001.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PE-CyTM5.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0018.jpg)
![Immunohistochemistry-Paraffin: CD45 Antibody (MEM-28) [NB500-319] - Staining of human small intestine (paraffin-embedded sections) with CD45 antibody (MEM-28), 10 ug/ml.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Immunohistochemistry-Paraffin-NB500-319-img0022.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Surface staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PerCP-CyTM5.5.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0007.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Surface staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) purified, GAM-APC.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0008.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Surface staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) APC-CyTM7.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0010.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) Pacific BlueTM.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0016.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PE.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0017.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PE-CyTM7.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0019.jpg)
![Flow Cytometry: CD45 Antibody (MEM-28) [NB500-319] - Staining of human peripheral blood cells with anti-human CD45 antibody (MEM-28) PE-DyLight (R) 594.](http://images.novusbio.com/fullsize/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0020.jpg)